Cantor Fitzgerald Thinks Neos Therapeutics’ Stock is Going to Recover


In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Neos Therapeutics (NEOS), with a price target of $20. The company’s shares opened today at $2.13, close to its 52-week low of $1.40.

Chen commented:

“. Post a solid quarter of execution in 1Q19, we reiterate our OW rating and 12-month PT of $20 for NEOS shares. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think the peak sales potential of its key drugs (Adzenys ER) as well as pipeline advancements (NT-0400 and NT-0502) will drive upwards earnings revisions to levels not reflected in consensus expectations and move NEOS’s stock higher.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 7.4% and a 40.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neos Therapeutics with a $20 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8 and a one-year low of $1.40. Currently, Neos Therapeutics has an average volume of 376.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts